FDA approval for Dupixent (dupilumab) in atopic dermatitis, adding efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement

These Phase III data are from the first and only trial evaluating a biologic specifically for this difficult-to-treat population and have also been added to the Dupixent label in the European Union, with regulatory submissions underway in additional countries.

Naimish Patel, M.D., Head of Global Development, Immunology and Inflammation, Sanofi, “Living with atopic dermatitis on your most essential body areas like the hands and feet can make daily activities including walking and writing incredibly burdensome even in the case where disease symptoms are mild elsewhere. Unfortunately, treating atopic dermatitis on the hands and feet has historically been difficult and there have been no Phase III trials evaluating a biologic in this population of patients. Having these data added for this difficult-to-treat population is important for physicians looking for tools to treat these patients and reinforces the already well-established efficacy and safety of Dupixent in atopic dermatitis overall.”

The label update is based on data from the Phase III LIBERTY-AD-HAFT trial. In the trial, patients received Dupixent (n=67) every two weeks (adults 300 mg, adolescents 200 mg or 300 mg based on body weight) or placebo (n=66). At 16 weeks, patients treated with Dupixent experienced the following: i. 40% achieved clear or almost clear skin on hands and feet compared to 17% with placebo, the primary endpoint. ii. 52% saw a clinically meaningful reduction in itch on hands and feet compared to 14% with placebo, the key secondary endpoint,.

Results from this Phase III trial were most recently accepted in the Journal of the American Academy of Dermatology.

The safety results were generally consistent with the known safety profile of Dupixent in atopic dermatitis. Most common adverse events (AEs) observed with Dupixent (?1%) in atopic dermatitis include injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye and eosinophilia.

See- " A real-world study of dupilumab in patients with atopic dermatitis including patients with malignancy and other medical comorbidities".:JAAD InternationalIn Press Accepted Manuscript Published online: January 15, 2024 -Dea Metk, oMaha Alkofide, Mohannad Abu-Hilal.